“We are honored to present and participate at this important event, and are looking forward to our continued partnership with NYBA to promote the life sciences and biotechnology communities throughout New York State and the lower Hudson Valley.”
Yonkers, NY (Vocus/PRWEB) April 06, 2011
Aureon Biosciences, Inc., will present at the New York Biotechnology Association's (NYBA) annual meeting. The meeting will take place on April 6th and 7th at the New York Marriott Marquis Hotel in New York City.
Dr. Charles J. DiComo, Corporate Compliance Officer, will present as part of a panel entitled “Novel Prognostic Genetic Tests for Cancer Patients” which will take place Wednesday, April 6th from 10:30 AM to 11:45 AM. Dr. DiComo’s presentation will focus on the clinical utility of Aureon’s prognostic testing, their uptake in the market place and how these tests impact treatment decisions for patients with prostate cancer.
“Aureon has been a proud supporter and member of NYBA for many years,” said Dr. Dicomo. “We are honored to present and participate at this important event, and are looking forward to our continued partnership with NYBA to promote the life sciences and biotechnology communities throughout New York State and the lower Hudson Valley.”
Dr. Jason Alter, Vice President of Marketing, will present as part of the NYBA 20th Annual Meeting Corporate Showcase which will also take place on Wednesday, April 6th at 2:40 PM. Dr. Alter’s presentation will focus on Aureon’s two commercially available prognostic tests for patients with prostate cancer. Aureon’s biopsy-based test, Prostate Px®+, is currently helping newly diagnosed prostate cancer patients make more informed treatment decisions. Prostate Px+ offers objective, comprehensive information about each patient’s disease from Aureon’s patented molecular analysis of the tumor. Dr. Alter will also discuss Aureon’s second test, Post-Op Px®, which utilizes prostatectomy tissue to provide more information to patients with high-risk features or anxiety post-surgery.
“Current risk assessment methods for prostate cancer patients are very limited due to their reliance on clinical and pathologic features which have become compressed,” said Dr. Alter. “During my presentation, I will present information showing how Aureon’s prognostic approach can provide an objective risk profile for patients that currently appear identical.”
About the New York Biotechnology Association
The mission of NYBA is to support the development and growth of New York State's biotechnology industry, and serve its members and the biotechnology community by providing a network for information exchange, shared services, and collective action. For more information please visit http://www.nyba.org.
About Aureon Biosciences
Aureon’s personalized, prognostic tools provide objective, comprehensive risk assessment both at diagnosis and after surgery. Prostate Px+ uses biopsy tissue at diagnosis to predict clinically significant disease as well as possible pathology changes post-surgery and is especially helpful for patients classified as low or intermediate risk. Post-Op Px provides objective information for post-surgical patients with a high risk feature (e.g., positive surgical margin, extracapsular extension) or any anxiety.
Aureon Biosciences mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit http://www.aureon.com or call 1-888-SYS-PATH.
# # #